HIGHLIGHTS
- who: Economics et al. from the Universidade Paulista, São Paulo, SP, Brazil have published the article: HealtH economics and management, in the Journal: (JOURNAL)
- what: An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer and patients with non-metastatic high-risk prostate cancer. The aim of pharmacoeconomics is to equate the increasing financial demand of new treatments with sustainability, so that the treatment for a specific subset of the population is available for everyone who will . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.